Article Text

PDF
P297 Lung-function profile before and after the first moderate to severe exacerbation during the wisdom study

Abstract

E Wouters, outside of the submitted work, reports personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Takeda, Pfizer and Boehringer Ingelheim, and grants from AstraZeneca, GlaxoSmithKline and Novartis.

H Magnussen received funding from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Takeda and Roche to conduct clinical studies, and has spoken at meetings and is a member of advisory boards for these and other companies.

R Rodriguez-Roisin reports personal fees from AstraZeneca, Boehringer Ingelheim, Mylan, Pearl Therapeutics, Takeda, Teva and Ferrer, and grants and personal fees from Menarini and Almirall.

K Tetzlaff and S Bell are employees of Boehringer Ingelheim Pharma GmbH & Co. KG. PMAC reports financial support in the form of a grant from Boehringer Ingelheim to conduct the study and, outside of the submitted work, reports personal fees from GlaxoSmithKline, AstraZeneca, Takeda and Boehringer Ingelheim, and grants from GlaxoSmithKline and Takeda.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.